

# Cardiorespiratory Coupling is Associated With Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease

**Yu-Chen Huang**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Ting-Yu Lin**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Hau-Tieng Wu**

Department of Mathematics, Duke University

**Po-Jui Chang**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Chun-Yu Lo**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Tsai-Yu Wang**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Chih-Hsi Scott Kuo**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Shu-Min Lin**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Fu-Tsai Chung**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Hong-Chyuan Lin**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Meng-Heng Hsieh**

Linkou Chang Gung Memorial Hospital: Chang Gung Memorial Hospital

**Yun Lun Lo** (✉ [loyulun@hotmail.com](mailto:loyulun@hotmail.com))

Department of Thoracic Medicine Chang Gung Memorial Hospital 199 Tun-Hwa N. Rd., Taipei, Taiwan

---

## Research article

**Keywords:** Heart-lung interaction, synchrogram index, six-minute walking distance, distance saturation product

**Posted Date:** November 2nd, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-99704/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on January 12th, 2021. See the published version at <https://doi.org/10.1186/s12890-021-01400-1>.

1 **Cardiorespiratory coupling is associated with exercise**  
2 **capacity in patients with chronic obstructive**  
3 **pulmonary disease**

4 Yu-Chen Huang<sup>1,2</sup> MD, Ting-Yu Lin<sup>1,2</sup> MD, Hau-Tieng Wu<sup>3,4</sup> MD, PhD, Po-Jui  
5 Chang<sup>1,2</sup> MD, PhD, Chun-Yu Lo<sup>1,2</sup> MD, PhD, Tsai-Yu Wang<sup>1,2</sup> MD, Chih-Hsi  
6 Scott Kuo<sup>1,2</sup> MD, Shu-Min Lin<sup>1,2</sup> MD, Fu-Tsai Chung<sup>1,2</sup> MD, Horng-Chyuan  
7 Lin<sup>1,2</sup> MD, Meng-Heng Hsieh<sup>1,2</sup> MD, Yu-Lun Lo<sup>1,2</sup> MD

8 *<sup>1</sup> Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei,*  
9 *Taiwan*

10 *<sup>2</sup> College of Medicine, Chang Gung University, Taoyuan, Taiwan*

11 *<sup>3</sup> Department of Mathematics, Duke University, Durham, NC, USA*

12 *<sup>4</sup> Department of Statistical Sciences, Duke University, Durham, NC, USA*

13

14 *Running title: Cardiorespiratory coupling in COPD*

15

16

Corresponding to:

17

**Yu-Lun Lo MD**

18

**Department of Thoracic Medicine**

19

**Chang Gung Memorial Hospital**

20

**199 Tun-Hwa N. Rd.,**

21

**Taipei, Taiwan**

22

**Fax: 886 33272474.**

23

**E-mail: loyulun@hotmail.com**

24

25 **This study was supported by a grant from the Taiwan Ministry of Science and**

26 **Technology, 107-2314-B-182A-145-MY2.**

27 **Abstract**

28 **Background:** Although comorbidities of cardiovascular disease is common in patients  
29 with chronic obstructive pulmonary disease (COPD), the interaction between the heart  
30 and lungs in COPD patients has yet to be further elucidated. Synchrogram index is a  
31 new parameter that can quantify this interaction and has the potential to apply in  
32 COPD patients.

33 **Aim:** Our objective in this study was to characterize cardiorespiratory interactions in  
34 terms of cardiorespiratory coupling (CRC) using the synchrogram index of the heart  
35 rate and respiratory flow signals in patients with chronic obstructive pulmonary  
36 disease.

37 **Methods:** This is a cross-sectional and a preliminary data from a prospective study,  
38 examining 55 COPD patients. K-means clustering analysis was applied to cluster  
39 COPD patients based on synchrogram index. Linear regression and multivariable  
40 regression analysis were used to determine the correlation between the synchrogram  
41 index and the exercise capacity assessed by six-minute walking test (6MWT).

42 **Results:** The 55 COPD patients were separated into a synchronized group (median  
43 0.89 (0.64-0.97), n=43) and a desynchronized group (median 0.23 (0.02-0.51), n=12)  
44 based on K-means clustering analysis. Synchrogram index was correlated  
45 significantly with six minutes walking distance ( $r=0.42$ ,  $p=0.001$ ) and distance

46 saturation product ( $r= 0.41$ ,  $p=0.001$ ) assessed by 6MWT, and still was an

47 independent variable by multivariable regression analysis.

48 **Conclusion:** This is the first result studying the heart-lung interaction in terms of

49 cardiorespiratory coupling in COPD patients by the synchrogram index, and COPD

50 patients are clustered into synchronized and desynchronized groups. Cardiorespiratory

51 coupling is associated with exercise capacity in patients with COPD.

52

53 **Key Words:** Heart-lung interaction, synchrogram index, six-minute walking distance,

54 distance saturation product.

## 55 **Background**

56 Chronic obstructive pulmonary disease (COPD) is characterized by irreversible  
57 airflow limitations resulting from the inflammation and narrowing of peripheral  
58 airway, destruction of the alveolar attachment, and loss of small airways [1-3].  
59 Possible causes include exposure to or inhalation of noxious gases or particles and  
60 systemic inflammation. COPD has been shown to affect nutritional status, exercise  
61 tolerance, and the cardiovascular system [4]. The prevalence of cardiovascular disease  
62 as a comorbidity and cause of mortality underlines the need to consider the interaction  
63 between the heart and lungs in patients with COPD [5-7].

64 Heart-lung interactions can be classified according to the underlying related but  
65 different mechanisms: (i) respiratory sinus arrhythmia, (ii) cardioventilatory coupling,  
66 and (iii) respiratory stroke volume synchronization [8]. For example, during  
67 inspiration, central inspiratory drive [9] and negative intrathoracic pressure [10] both  
68 contribute to an increase in heart rate [11]. Negative intrathoracic pressure promotes  
69 filling of the right ventricle and impedes filling of the left ventricle [12]. A decrease  
70 in arterial blood pressure tends to increase respiratory rate and tidal volume through  
71 the baroreflex [13]. Since heart-lung interactions was affected by several mechanisms  
72 as mentioned before, a proper quantification of cardiorespiratory coupling (CRC) is

73 an intuitive method to depict it.-It has been used to study the heart-lung interactions in  
74 control subjects [14], infants [15], and in identifying sleep stages [16].

75 To our knowledge, CRC has not been systematically evaluated in patients. Under  
76 the clinical observation of intimate relationship between heart and lung in patients  
77 with COPD [17], a proper quantification of CRC would be beneficial for clinical  
78 application. The aim of this study was to apply synchrogram index to evaluate the  
79 CRC in patients with COPD, and to cluster patients based on their synchrogram  
80 index.

## 81 **Methods**

### 82 **Study Design and Patients**

83 This observational cross-sectional study was a preliminary data from a conducting  
84 prospective study at Chang Gung Memorial Hospital since January in 2019.

85 Included patients were those with a clinical diagnosis COPD, based on the Global  
86 Initiative for Obstructive Lung Disease Criteria (GOLD), with the exclusive criteria:  
87 patients with congestive heart failure (ejection fraction <40%), known malignancy, or  
88 atrial fibrillation as well as those using anti-arrhythmic agents for arrhythmia or  
89 oxygen. All COPD patients underwent cardiac echo analysis, biochemical analysis  
90 (eosinophils, high sensitivity C-reactive protein (HS-CRP), and IgE), pulmonary  
91 function tests, chest high-resolution CT (HRCT) scanning, a six-minute walking test

92 (6MWT) and a coupling test during the first visit of enrollment. Emphysema was  
93 defined based on chest HRCT report from the radiologist and one pulmonologist [18].  
94 Clinical profiles, a list of inhalation medicines, anti-psychotic agents, result of  
95 emphysema based on HRCT and acute exacerbation history [19] were also recorded.  
96 Although there is one patient who presented high ratio of FEV<sub>1</sub>/FVC before exercise  
97 (0.72) and after exercise (0.73), he was not excluded as the spirometry fulfilled the  
98 GOLD guideline when he was diagnosed COPD. The remaining 55 patients with  
99 COPD (69 (51-84) years old, 54 male) (Figure 1). All participants signed informed  
100 consent prior to enrollment. The study was approved by the Ethics Committee of  
101 Chang Gung Memorial Hospital, Linkou, Taiwan (201702150B0).

### 102 **Six-minute walking test**

103           The 6MWT was carried out on the smooth surface and straight aisle with  
104 interval of 30 meters. Before the exam, patients were rest in a sitting position and  
105 performed spirometry before exercise to assess the pulmonary function, including the  
106 flow volume and tidal volume based on the guideline [20]. Meanwhile, oxygen  
107 saturation, heart rate, arterial blood pressure, and Borg scale in assessing the degree of  
108 dyspnea were recorded. Then, they were instructed to walk as soon as possible in six  
109 minutes. They could stop and take the rest when they felt tired or dyspnea, then  
110 restarted if they are available as soon as possible. The instructors were avoided to

111 walk with the subjects but stood at the fixed area giving encouraging sentences with  
112 even tone every minute and 15 second before the end of the exam according to the  
113 American Thoracic Society (ATS) guideline [21, 22]. Oxygen saturation and heart  
114 rate can be recorded in real time during the course of walking. At the end of the exam,  
115 walking distance, oxygen saturation, distance saturation product (i.e., the product of  
116 nadir saturation during exercise and walking), heart rate and Borg scale were recorded  
117 and patients performed spirometry again after exercise.

#### 118 **Phase synchronization analysis**

#### 119 **Instrumentation**

120 Experiments were performed in a quiet room with the temperature maintained at  
121 22-24 °C. Participants were instructed to avoid inhalation short acting bronchodilators  
122 for 4 hours and oral medicines such as beta-2 agonists, xanthene derivatives for 12  
123 hours, and alcohol or caffeine-contained drink for at least eight hours prior to the test.  
124 Otherwise, participants could intake other foods before the exam. The chest skin was  
125 abraded using gel and then cleaned using alcohol to reduce electrode impedance prior  
126 to the attachment of electrocardiogram (ECG) electrodes. Prior to the examination,  
127 recordings of blood pressure, heart rate, and oxygen saturation were obtained. The  
128 subjects wore a pulse oximeter on the index finger and ECG electrodes on the chest  
129 wall. Before the exam, the breathing tube was inserted into the subject's mouth with

130 their lips are sealed around the mouthpiece and the nose clip of the nares was used  
131 [23]. The subject was instructed to practice breathing at tidal volume for 1 minute  
132 then complete exam in the same way when they were ready. ECG signals and flow  
133 signals were recorded continuously for 5 min using three Actiwave devices  
134 (CamNtech Ltd, Cambridge, UK). The recorded signals were transferred in European  
135 Data Format to LabChart 8 software (ADInstruments, Dunedin, New Zealand), and  
136 then exported to text files for analysis.

### 137 **Signal Processing and Synchrogram index**

138 R peaks were detected using a standard R peak detection algorithm from the ECG  
139 signal (Figure 2 (a5 and b5)). The time differences between consecutive R peaks were  
140 calculated, and then converted into an instantaneous heart rate (IHR) time series using  
141 a standard interpolation algorithm (Figure 2 (a4 and b4)) [24]. The phase of the  
142 respiratory signal (denoted as  $\phi_R$ ) was extracted using the synchrosqueezing  
143 transform (SST) (Figure 2 (a3 and b3) [25]. The phase of IHR (denoted as  $\phi_H$ ) was  
144 extracted by the same method (Figure 2 (a2 and b2)). After obtaining the phases of the  
145 IHR and the respiratory signal, the synchrogram was used to quantify the  
146 cardiorespiratory coupling [14, 26]. The output is the synchrogram index, which is a  
147 non-unit quantity between 0 and 1. When the cardiorespiratory coupling is strong, the  
148 synchrogram index is close to 1; otherwise it is close to 0.

149 The synchrogram is a signal processing tool used to depict coupling between two  
150 oscillatory signals. In the current study, we first obtained the timestamps  $t_k$  (Figure 2  
151 (dashed line between a2 and a3, b2 and b3)), where the IHR phase attained 0 modulo  
152  $2\pi$ . We then measured the respiratory phase at  $t_k$  as follows:  $\psi(t_k) =$   
153  $\frac{1}{2\pi} [\phi_R(t_k) \bmod 2\pi]$ ; that is, we evaluate the phase of the respiratory signal at  $t_k$   
154 (Figure 2 (circle points at a2 and b2)). Finally, plot  $\psi(t_k)$  against  $t_k$ . When the  
155 cardiorespiratory coupling is strong, the phase of the respiratory signal at  $t_k$  would  
156 be fixed for all  $k$ , and hence we obtain a horizontal stripe in the plot (Figure 2 (a6)) ;  
157 otherwise, we obtained scattered points in the plot (Figure 2 (b6)). The *synchrogram*  
158 *index*  $\lambda$  [26] is aiming to quantify if the plot is scattered or fixed along a horizontal  
159 line. It is defined by  $\lambda = \frac{1}{M} \left[ \left( \sum_{t_k=1}^M \sin 2\pi \psi(t_k) \right)^2 + \left( \sum_{t_k=1}^M \cos 2\pi \psi(t_k) \right)^2 \right]$ , where  
160  $M$  is the number of detected cycles in the IHR.

## 161 **Statistical Analysis**

162 All results are presented as median (range) or mean  $\pm$  standard deviation. The  
163 nonparametric exact two-tailed Mann-Whitney U test was used to determine the  
164 statistical significance between two groups of continuous variables, and Fisher's exact  
165 tests were used for categorical variables. Pearson's correlation was used to examine  
166 the association between six-minute walking distance (6MWD), distance saturation  
167 product (DSP) and clinical parameter, including synchrogram index. Multivariable

168 regression analysis was used to determine the independent parameters that predict  
169 distance. K-Means was applied to cluster COPD patients based on their synchrogram  
170 indices. Silhouette analysis was performed to select optimal cluster numbers. All  
171 reported P values were two-sided, with  $P < 0.05$  considered statically significant.  
172 Signals were analyzed using Matlab. All data were analyzed using R version 3.5.2 (R  
173 foundation for statistical computing).

## 174 **Results**

### 175 **Demographic characteristics of patient**

176 Among 55 COPD patients, 54 (98.2%) were male, 49 (89.1%) had smoking  
177 history, 36 (65.5%) were in allergic status, 33 (60%) were confirmed with  
178 emphysema from chest HRCT, and only 1 (1.8%) patient fulfilled the criteria of  
179 Asthma-COPD overlap (ACO) [27, 28]. The median synchrogram indices in the  
180 COPD group was 0.87 and the distribution was skewed (range: 0.02-0.97). The  
181 median BMI was 24.7 (range 16.7-32.1) modified medical research council (mMRC)  
182 was 1 (range 0-4), and COPD assessment test (CAT) was 10 (range 2-29). The  
183 median ejection fraction was 65.5% (range 52-90), suggesting that there was no heart  
184 failure mid-range ejection fraction (HFmrEF) patient in COPD group. However, there  
185 were 24 patients (44.3%) presented diastolic dysfunction. The median left atrial size  
186 was 34 mm (range 23-46) and E/e' ratio (the ratio of the transmitral early peak

187 velocity over early diastolic mitral annulus velocity) was 8.9 (4.5-20.0). In addition,  
188 the median eosinophil count was 129 (range 0-615.6), IgE level was 59.7 (2-1652)  
189 and 19 (34.5%) patients had a history of acute exacerbation one year prior to  
190 enrollment in the study. Most patients used combination therapy of long-acting  $\beta_2$   
191 agonist (LABA) with long-acting muscarinic antagonist (LAMA) (20 (36.4%)) and  
192 triple therapy of LABA with LAMA and ICS (26 (47.3%)) (Table 1).

### 193 **ECG, flow signal, CRC data, and synchrogram index**

194 Figures 2a and 2b illustrate CRC analysis based on the synchrogram of IHR and  
195 respiratory flow signals. Since there are no definitions of good or poor  
196 synchronization, we applied K-means [29]. Two clusters were identified, i.e.  
197 synchronized group (n=43) and desynchronized group (n=12) according to the  
198 optimal cluster number based on the silhouette analysis. The median synchrogram  
199 index values in these two groups were as follows: synchronized group (0.89; 0.64-  
200 0.97) and desynchronized group (0.23; 0.02-0.51) (Figure 3b). Overall, subjects in the  
201 synchronized group were younger (69 (51-84) vs 77 (52-84), p= 0.02) and had a  
202 lower BMI (24.2 (16.7-32) vs 26.2 (20.3-30.8), p =0.03). No significant between-  
203 group differences were observed in terms of gender, smoking status, allergic status,  
204 therapies, or history of acute exacerbation (Table 1).

### 205 **Comparing coupling tests with six-minute walking test**

206 In terms of 6MWT, patients in the synchronized group presented longer walking  
207 distances (468 (328-624) vs. 408 (182-517), unit=m, p =0.009) and a higher distance  
208 saturation product (DSP) (421.2 (255.6-536.6), vs 373.2 (149.2-464.6), unit=m%,  
209 p=0.02) (Table 2).The correlation of distance and DSP assessed by 6MWT with  
210 clinical parameters were listed (Table 3). The synchrogram index correlated  
211 significantly with distance (r=0.42, p =0.001) (Figure 3c) and DSP (r=0.41, p= 0.001)  
212 (Figure 3d). In the multivariable regression model, age, mMRC and synchrogram  
213 index were independent variables that could predict distance. Age, synchrogram  
214 index, mMRC, emphysema were independent variables to predict DSP (Table 4).  
215 Distance was explained by the following multivariable regression model with three  
216 independent variables: (1) Distance = 671.3+93.3×Synchrogram Index-3.1×Age-  
217 37.9×mMRC (r<sup>2</sup>= 0.56, p <0.0001) (2) DSP= 619.2+89.1×Synchrogram Index-  
218 2.8×Age-50.7×mMRC-41.1×Emphysema (r<sup>2</sup>= 0.63, p <0.0001).

## 219 **Discussion**

220 This is the first study to cluster COPD patients into synchronized or  
221 desynchronized patients in terms of cardiorespiratory coupling. The synchrogram  
222 index distribution was wide among COPD patients and narrow among control  
223 subjects. Patients in synchronized group presented the similar distribution of  
224 synchrogram index to that among control subjects and had higher 6MWD and DSP

225 compared with desynchronized group. In addition to the factors previously identified,  
226 synchrogram index is a novel factor that was and independent variable to predict  
227 6MWD and DSP.

228           Researchers have previously demonstrated that six-minute walking distance  
229 is an important predictor of survival in COPD patients [30, 31] and heart failure  
230 patients [32]. The poor walking distance demonstrated by COPD patients can be  
231 attributed to age [33], desaturation [34],the severity of emphysema [35], dyspnea  
232 scores [36], and inspiratory capacity [37]. Our study has the coordinate results that  
233 age and mMRC contribute to 6MWD, and reveal that synchrogram index is a factor in  
234 determining 6MWD. The influence of cardiorespiratory coupling on the prognosis of  
235 COPD patients should be further confirmed under adequate follow-up duration.

236           In terms of patients with heart failure, several comorbid conditions, such as  
237 skeletal muscle dysfunction, impaired autonomic regulation, and nutritional factors,  
238 may coexist and contribute to exercise intolerance [38]. Furthermore, impaired  
239 aerobic function due to negative cardiopulmonary muscular interaction contributes to  
240 low exercise intolerance in patients with COPD and in those suffering from heart  
241 failure [39]. In this study, there is no HFmrEF patient. Moreover, we found that  
242 diastolic heart failure was not related to walking distance. This is an indication that  
243 walking distance is independent of impaired pulmonary or heart function. Instead, it

244 appears that nutritional status, peripheral muscle condition [40], oxygen utilization by  
245 peripheral muscle, and negative cardiorespiratory-muscle interactions [39] should be  
246 taken into account. Since synchrogram index is a quantification of heart lung  
247 interaction, its relationship with oxygen utilization by peripheral muscle and  
248 cardiopulmonary muscle interactions should be further explored to explain the  
249 underlying mechanism why synchrogram index was associated with walking distance.

250 DSP is a reliable factor to predict mortality among patients with bronchiectasis  
251 [41], interstitial lung disease [42], and COPD [43, 44]. In this study, patients in the  
252 desynchronized group present a lower DSP, implying an elevated likelihood of poor  
253 outcomes but need adequate follow-up duration to confirm. To our knowledge, this is  
254 the first study to evaluate factors that associated with DSP in COPD patients. Age,  
255 mMRC, synchrogram index and emphysema are independent variables to predict DSP.  
256 Emphysema is an independent factor in determining DSP but not 6MWD in this  
257 study, which may be related to the correlation of emphysema among desaturation  
258 during exercise [45] and its contribution to the desaturation component of DSP.

259 A strong heart-lung interaction may improve ventilation and perfusion matching,  
260 resulting in a better oxygen transport [46]. However, we did not observe any  
261 discrepancy between the synchronized and desynchronized groups in terms of  
262 saturation. This may be explained by the fact that we excluded patients who were

263 using oxygen on a daily basis and by the reason that there was similar proportion of  
264 emphysema. Note that there may be a link between desaturation and coupling in those  
265 patients. In order to evaluate this relationship, it is necessary to explore COPD  
266 patients with chronic hypoxemic failure in the next program.

267         This study faced a number of limitations. First, despite measuring and  
268 quantifying the coupling between respiration flow signals and IHR, we found no  
269 indications of causality. Second, the strict inclusion criteria prevented us from  
270 analyzing patients using oxygen on a daily basis, thus there was small population of  
271 desynchronized subgroup in this study. Third, most of the patients in the study were  
272 male and all were of East Asian decent; i.e., this sample is not representative of  
273 COPD patients overall. Finally, this is a cross-sectional and preliminary data of a  
274 prospective-designed study. Due to the insufficient follow-up time, we cannot  
275 evaluate mortality outcomes and cardiac vascular events. We will continue  
276 monitoring the subjects in this study in order to observe the clinical impact of  
277 synchronization in heart-lung interactions.

## 278 **Conclusions**

279         This study first conducted the CRC analysis to describe heart-lung interactions of  
280 COPD patients. Besides from age and mMRC, synchrogram index is an independent  
281 variable that could predict 6MWD and DSP.

282

283 **List of abbreviations:** ACO: Asthma-COPD overlap; AE: acute exacerbation;  
284 BMI: body mass index; CAT: chronic obstructive pulmonary disease assessment test;  
285 COPD: chronic obstructive pulmonary disease; CRC: cardiorespiratory coupling;  
286 ECG: electrocardiogram; ETCO<sub>2</sub> sensor: end tidal CO<sub>2</sub> sensor; FEV<sub>1</sub>: forced  
287 expiratory volume in 1<sup>st</sup> second; FVC: forced vital capacity; GOLD: Global Initiative  
288 for Obstructive Lung Disease Criteria; HRV: heart rate variability; HS-CRP: high  
289 sensitivity C-reactive protein; ICS: inhaled corticosteroids; IHR: instantaneous heart  
290 rate; mMRC: modified medical research council; LABA: long-acting beta agonists;  
291 LAMA: long-acting antimuscarinic agents; OCS: oral corticosteroids; SST:  
292 synchrosqueezing transform

293

## 294 **Declarations**

### 295 *Ethics approval and consent to participate*

296 The study was approved by the Ethics Committee of Chang Gung Memorial Hospital,  
297 Linkou, Taiwan (201702150B0). Patients provided signed informed consent prior to  
298 screening.

### 299 *Consent for publication*

300 Not Applicable.

301 *Availability of data and materials*

302 The data sets analyzed during the current study are available from the corresponding  
303 author upon reasonable request.

304 *Competing interests*

305 All authors all declare that they have no competing interests.

306 *Funding*

307 **This study was supported by a grant from the Taiwan Ministry of Science and  
308 Technology, 107-2314-B-182A-145-MY2.**

309 *Authors' contributions*

310 TYL, HTW, PJC, CYL and YLL conceived and designed the analysis. SML MHH,  
311 FTC, TYW and HCL contributed to the clinical and laboratory work for the study.  
312 YLL, HTW, and YCH designed and performed the statistical analyses. All authors  
313 were involved in data analysis, data interpretation, and preparation of the final  
314 manuscript. The authors read and approved the final manuscript.

315 *Acknowledgements*

316 We thank all the investigators and members of the Department of Thoracic Medicine  
317 for their effort.

318 **References:**

- 319 1. Scichilone N, Bruno A, Marchese R, et al. Association between reduced  
320 bronchodilatory effect of deep inspiration and loss of alveolar attachments.  
321 Respiratory research. 2005; 6(1): 55.
- 322 2. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and  
323 emphysema in chronic obstructive pulmonary disease. New England Journal  
324 of Medicine. 2011; 365(17): 1567-75.
- 325 3. Global Initiative For Chronic Obstructive Lung Disease pocket guide to  
326 COPD diagnosis, management, and prevention. 2020.
- 327 4. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis,  
328 management, and prevention of chronic obstructive pulmonary disease:  
329 GOLD executive summary. American journal of respiratory and critical care  
330 medicine. 2007; 176(6): 532-55.
- 331 5. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD.  
332 European Respiratory Journal. 2008; 31(1): 204-212.
- 333 6. Godtfredsen NS, LAM TH, Hansai TT, et al. COPD-related morbidity and  
334 mortality after smoking cessation: status of the evidence. European  
335 Respiratory Journal. 2008; 32(4): 844-53.
- 336 7. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest.  
337 2011; 139(1): 165-73.
- 338 8. Elstad M, O’Callaghan EL, Smith AJ, et al. Cardiorespiratory interactions in  
339 humans and animals: rhythms for life. American Journal of Physiology-Heart  
340 and Circulatory Physiology. 2018; 315(1): 6-17.
- 341 9. Baekey DM, Dick TE, Paton JF. Pontomedullary transection attenuates central  
342 respiratory modulation of sympathetic discharge, heart rate and the  
343 baroreceptor reflex in the in situ rat preparation. Experimental physiology.  
344 2008; 93(7): 803-16.
- 345 10. Lopes OU, Palmer J. Proposed respiratory ‘gating’ mechanism for cardiac  
346 slowing. Nature. 1976; 264(5585): 454.
- 347 11. Ben-Tal A, Shamailov SS, Paton JF. Central regulation of heart rate and the  
348 appearance of respiratory sinus arrhythmia: New insights from mathematical  
349 modeling. Mathematical biosciences. 2014; 255: 71-82.
- 350 12. Elstad M. Respiratory variations in pulmonary and systemic blood flow in  
351 healthy humans. Acta physiologica. 2012; 205(3): 341-8.
- 352 13. De Burgh Daly, M. Interactions between respiration and circulation.  
353 Comprehensive Physiology. 2011; 529-94.
- 354 14. Schäfer C, Rosenblum MG, Kurths J et al. Heartbeat synchronized with

- 355 ventilation. *nature*. 1998. 392(6673): 239.
- 356 15. Mrowka R, Patzak A, Rosenblum M, et al. Quantitative analysis of  
357 cardiorespiratory synchronization in infants. *International Journal of*  
358 *Bifurcation and Chaos*. 2000. 10(11): 2479-88.
- 359 16. Niizeki K, Saitoh T. Association between phase coupling of respiratory sinus  
360 arrhythmia and slow wave brain activity during sleep. *Frontiers in physiology*.  
361 2018; 9: 1338.
- 362 17. Cheyne WS, Williams AM, Harper MI, et al. Heart-lung interaction in a model  
363 of COPD: importance of lung volume and direct ventricular interaction.  
364 *American Journal of Physiology-Heart and Circulatory Physiology*. 2016.  
365 311(6): 1367-74.
- 366 18. Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based  
367 on severity of emphysema in chronic obstructive pulmonary disease. *Thorax*.  
368 2007; 62(11): 932-7.
- 369 19. Rodriguez-Roisin R. Toward a Consensus Definition for COPD  
370 Exacerbations. *CHEST*. 2000; 117: 398-401.
- 371 20. Przybyłowski T, Tomalak W, Siergiejko Z, et al. Polish Respiratory Society  
372 guidelines for the methodology and interpretation of the 6 minute walk test  
373 (6MWT). *Advances in Respiratory Medicine*. 2015; 83(4): 283-97.
- 374 21. Crapo RO, Hankinson JL, Irvin C, et al. Standardization of spirometry: 1994  
375 update. *American Journal of Respiratory and Critical Care Medicine*. 1995;  
376 152(3): 1107-36.
- 377 22. ATS committee on proficiency standards for clinical pulmonary function  
378 laboratories. *Am J Respir Crit Care Med*. 2002; 166(1): 111-7.
- 379 23. Miller MR, Hankinson JATS, Brusasco V, et al. Standardisation of spirometry.  
380 *European respiratory journal*. 2005; 26(2): 319-38.
- 381 24. Camm AJ, Malik M, Bigger JT, et al. Heart rate variability: standards of  
382 measurement, physiological interpretation and clinical use. Task Force of the  
383 European Society of Cardiology and the North American Society of Pacing  
384 and Electrophysiology. 1996.
- 385 25. Daubechies I, Lu J, Wu HT, et al. Synchrosqueezed wavelet transforms: An  
386 empirical mode decomposition-like tool. *Applied and computational harmonic*  
387 *analysis*. 2011;30(2): 243-61.
- 388 26. Nguyen CD, Wilson SJ, Crozier S, et al. Automated quantification of the  
389 synchrogram by recurrence plot analysis. *IEEE Transactions on Biomedical*  
390 *Engineering*. 2012; 59(4): 946-55.
- 391 27. Sin DD, Miravitlles M, Mannino DM, et al. What is asthma– COPD overlap  
392 syndrome? Towards a consensus definition from a round table discussion.

- 393 European Respiratory Journal. 2016; 48(3): 664-73.
- 394 28. Maselli DJ, Hardin M, Christenson SA, et al. Clinical approach to the therapy  
395 of asthma-COPD overlap. *Chest*. 2019; 155(1): 168-77.
- 396 29. Hartigan J, Wong M. AK-Means Clustering Algorithm. *Journal of the Royal*  
397 *Statistical Society Series C*. 1979; 28(1): 100-8.
- 398 30. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic  
399 obstructive pulmonary disease: minimal clinically important difference for  
400 death or hospitalization. *American journal of respiratory and critical care*  
401 *medicine*. 2013; 187(4): 382-6.
- 402 31. Pinto-Plata V, Cote C, Cabral H, et al. The 6-min walk distance: change over  
403 time and value as a predictor of survival in severe COPD. *European*  
404 *Respiratory Journal*. 2004; 23(1): 28-33.
- 405 32. Rubim, V.S.M., et al., Prognostic value of the six-minute walk test in heart  
406 failure. *Arquivos brasileiros de cardiologia*, 2006. 86(2): p. 120-125.
- 407 33. Peruzza S, Sergi, G, Vianello, A, et al. Chronic obstructive pulmonary disease  
408 (COPD) in elderly subjects: impact on functional status and quality of life.  
409 *Respiratory medicine*. 2003; 97(6): 612-7.
- 410 34. Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6-min  
411 walking distance in patients with COPD: the ECLIPSE cohort. *Respiratory*  
412 *medicine*. 2010; 104(6): 849-57.
- 413 35. Díaz AA, Pinto-Plata V, Hernández C, et al. Emphysema and DLCO predict a  
414 clinically important difference for 6MWD decline in COPD. *Respiratory*  
415 *medicine*. 2015; 109(7): 882-9.
- 416 36. Guo Y, Zhang X, Chen J, et al. Value of CAT and mMRC in clinical evaluation  
417 of chronic obstructive pulmonary disease. *Chongqing Medicine*, 2014; (11):  
418 1304-7.
- 419 37. Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic  
420 hyperinflation, breathlessness, and exercise performance during the 6-minute-  
421 walk test in chronic obstructive pulmonary disease. *American journal of*  
422 *respiratory and critical care medicine*. 2001; 163(6):1395-9.
- 423 38. Del Buono MG, Arena R, Borlaug BA, et al. Exercise intolerance in patients  
424 with heart failure: JACC State-of-the-Art Review. *Journal of the American*  
425 *College of Cardiology*. 2019; 73(17): 2209-25.
- 426 39. Rocha A, Arbex FF, Sperandio PA, et al. Exercise intolerance in comorbid  
427 COPD and heart failure: the role of impaired aerobic function. *European*  
428 *Respiratory Journal*. 2019; 53(4): 1802386.
- 429 40. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new  
430 outcome measure in Duchenne muscular dystrophy. *Muscle & Nerve: Official*

- 431 Journal of the American Association of Electrodiagnostic Medicine. 2010;  
432 41(4): 500-10.
- 433 41. Hsieh MH, Fang YF, Chung FT, et al. Distance-saturation product of the 6-  
434 minute walk test predicts mortality of patients with non-cystic fibrosis  
435 bronchiectasis. *Journal of thoracic disease*. 2017; 9(9): 3168.
- 436 42. Lettieri CJ, Nathan SD, Browning RF, et al. The distance-saturation product  
437 predicts mortality in idiopathic pulmonary fibrosis. *Respiratory medicine*.  
438 2006; 100(10): 1734-41.
- 439 43. Andrianopoulos V, Wouters EF, Pinto-Plata VM, et al. Prognostic value of  
440 variables derived from the six-minute walk test in patients with COPD: results  
441 from the ECLIPSE study. *Respiratory medicine*. 2015; 109(9): 1138-46.
- 442 44. Gurbani N, Figueira Gonçalves JM, García Bello MA, et al. Prognostic ability  
443 of the distance-saturation product in the 6-minute walk test in patients with  
444 chronic obstructive pulmonary disease. *The Clinical Respiratory Journal*.  
445 2020; 14(4): 364-9.
- 446 45. Andrianopoulos V, Celli BR, Franssen FM, et al. Determinants of exercise-  
447 induced oxygen desaturation including pulmonary emphysema in COPD:  
448 Results from the ECLIPSE study. *Respiratory medicine*. 2016; 119: 87-95.
- 449 46. Yasuma F, Hayano J. Respiratory sinus arrhythmia: why does the heartbeat  
450 synchronize with respiratory rhythm? *Chest*. 2004; 125(2): 683-90.
- 451

**Table 1 Clinical characteristics of COPD patients, clustered into synchronized and desynchronized group**

Variable median (range)	Total (n=55)	Synchronized (n=43)	Desynchronized (n=12)	p-value
<b>Age</b>	69 (51-84)	69 (51-84)	77 (52-84)	0.02
<b>Gender, male</b>	54 (98.2)	42 (97.7)	12 (100)	1
<b>Smoker</b>	49 (89.1)	38 (88.4)	11 (91.7)	1
<b>Current</b>	27 (49.1)	20 (46.5)	7 (58.3)	1
<b>Ex-smoker</b>	22 (40)	17 (39.5)	5 (41.7)	1
<b>BMI</b>	24.7 (16.7-32.1)	24.2 (16.7-32.0)	26.2 (20.3-30.8)	0.03
<b>Eosinophil Count</b>	129 (0-615.6)	134.5 (0-615.6)	115.0 (0-329.8)	0.74
<b>Allergy</b>	36 (65.5)	28 (65.1)	8 (66.7)	1
<b>a-IgE</b>	59.7 (2-1652)	65.2 (3.59-1652)	47.0 (2-691)	0.59
<b>HS-CRP</b>	1.7 (0.2-189.7)	1.64 (0.2-37.9)	1.75 (0.2-189.7)	0.65
<b>CAT</b>	10 (2-29)	10 (2-29)	6 (3-29)	0.99
<b>mMRC</b>	1 (0-4)	1 (0-3)	1 (0-4)	0.73
<b>Emphysema</b>	33 (60)	27 (62.7)	6 (50)	1
<b>AE history</b>	19 (34.5)	16 (37.2)	3 (25)	0.49
<b>Underlying</b>				
<b>ACO</b>	1 (1.8)	0 (0)	1 (8.3)	0.21
<b>Hypertension</b>	17 (30.9)	11 (25.6)	6 (46.2)	0.16
<b>DM</b>	8 (14.5)	5 (11.6)	3 (23.1)	0.35
<b>CAD</b>	3 (5.5)	3 (7.0)	0 (0)	1
<b>Liver Disease</b>	6 (10.9)	6 (14.0)	0 (0)	0.32
<b>Kidney Disease</b>	1 (1.8)	0 (0)	1 (7.7)	0.21
<b>Cardiac echo</b>				
<b>Diastolic dysfunction</b>	24 (43.6)	20 (46.5)	4 (33.3)	0.51
<b>E/e' ratio</b>	8.9 (4.5-20.0)	8.8 (4.5-13.0)	11.4 (5.2-20.0)	0.06
<b>EF (%)</b>	65.5 (52-90)	66.5 (52-90)	64.5 (52-78)	0.33
<b>LA (mm)</b>	34 (23-46)	34 (23-46)	33.5 (28-41)	0.99
<b>Drugs</b>				
<b>LABA</b>	4 (7.3)	3 (7.0)	1 (8.3)	1
<b>LAMA</b>	1 (1.8)	1 (2.3)	0 (0)	1
<b>LABA+LAMA</b>	20 (36.4)	15 (34.9)	5 (41.7)	0.74
<b>LABA+ICS</b>	3 (5.5)	2 (4.7)	1 (8.3)	0.54
<b>Triple</b>	26 (47.3)	22 (51.2)	4 (33.3)	0.35
<b>OCS</b>	5 (9.1)	4 (9.3)	1 (8.3)	1
<b>Anti-psychotic agents</b>	2 (3.6)	0 (0)	2 (4.8)	1

Significantly different from patients with synchronized and desynchronized (P < 0.05). Abbreviation: BMI (Body mass index), HS-CRP (High sensitivity C reactive protein), CAT (Chronic obstructive pulmonary disease assessment test), mMRC (modified medical research council), E/e' ratio (the ratio of the transmitral early peak velocity over early diastolic mitral annulus velocity), EF (Ejection fraction), LA (left atrial) LABA (Long acting beta agonists), LAMA (Long acting antimuscarinic agents), ICS (inhaled corticosteroids), Triple (LABA+LAMA+ICS), OCS (oral corticosteroids), AE (acute exacerbation)

**Table 2 Results of 6MWT in COPD patients, synchronized and desynchronized group**

	COPD (n=55)	Synchronized (n=43)	Desynchronized (n=12)	p-value
<b>Pre-and post-exercise (6MWT)</b>				
<b>Median (range)</b>				
<b>Pre-FVC(L)</b>	2.6 (1.2-4.4)	2.7 (1.2-4.4)	2.45 (1.3-3.3)	0.28
<b>Pre-FVC (%)</b>	78.7 (38-129)	82.5 (39-129)	77 (38-96)	0.89
<b>Pre-FEV1(L)</b>	1.5 (0.5-2.7)	1.39 (0.6-2.7)	1.43 (0.5-2.0)	0.49
<b>Pre-FEV1(%)</b>	56.7 (18-102)	55.5 (18-102)	62.5 (18-76)	0.79
<b>Pre-FEV1/FVC</b>	0.56 (0.31-0.72)	0.57 (0.31-0.72)	0.56 (0.35-0.7)	0.64
<b>Post-FVC(L)</b>	2.7 (1.1-4.4)	2.7 (1.1-4.4)	2.7 (1.4-3.3)	0.29
<b>Post-FVC %</b>	81 (42-130)	81.5 (42-130)	87 (43-96)	0.78
<b>Post-FEV1 (L)</b>	1.47 (0.53-2.82)	1.44 (0.67-2.82)	1.49 (0.53-2.09)	0.53
<b>Post-FEV1(%)</b>	60 (21-105)	57 (22-105)	60 (21-79)	0.60
<b>Post-FEV1/FVC</b>	0.59 (0.35-0.73)	0.59 (0.35-0.73)	0.56 (0.37-0.70)	0.62
<b>Pre-HR</b>	83 (57-109)	83.5 (57-109)	80.5 (60-98)	0.66
<b>Post-HR</b>	107 (69-149)	108 (69-149)	105 (70-122)	0.48
<b>Pre-Borg</b>	0 (0-3)	0 (0-3)	1 (0-3)	0.06
<b>Post-Borg</b>	4 (1-7)	4 (2-7)	4 (1-7)	0.77
<b>pre-spO2</b>	95 (88-99)	95.5 (88-99)	95 (90-98)	0.31
<b>post-spO2</b>	90.5 (75-96)	90.5 (75-96)	90 (80-95)	0.61
<b>pre-IC</b>	1.78 (0.92-2.77)	1.78 (1.07-2.77)	1.73 (0.92-2.04)	0.20
<b>post-IC</b>	1.73 (0.94-2.83)	1.73 (0.97-2.83)	1.7 (0.94-2.43)	0.45
<b>ΔIC</b>	0 (-1.1-0.55)	-0.02 (-0.49 - 0.55)	0.11(-1.1-0.28)	0.37
<b>ΔspO2</b>	-4.5 (-22~0)	-4.5 (-22~0)	-4.0 (-18~0)	0.97
<b>Distance</b>	456 (182-624)	468 (328-624)	408 (182-517)	0.03
<b>DSP</b>	411.1 (149.2-536.6)	421.2 (255.6-536.6)	373.2 (149.2-464.6)	0.04

Significantly different from patients with Synchronized and Desynchronized (P < 0.05). Abbreviation: 6MWT (six minutes walking test), FVC (Forced vital capacity), FEV1 (Forced expiratory volume in 1st second), HR (Heart rate), ΔIC (change of inspiratory capacity), ΔspO2 (change of oxyhemoglobin saturation by pulse oximetry), DSP (Distance saturation product)

**Table 3 Main correlations with distance and DSP as Assessed by 6MWT**

Variable	Distance		DSP	
	r Value	p Value	r Value	p Value
<b>Age</b>	-0.53	<0.001	-0.53	<0.001
<b>Synchrogram Index</b>	0.42	0.001	0.41	0.001
<b>BMI</b>	-0.07	0.62	-0.05	0.69
<b>Gender</b>	0.13	0.34	0.17	0.21
<b>CAT</b>	-0.44	<0.001	-0.44	<0.001
<b>mMRC</b>	-0.53	<0.001	-0.61	<0.001
<b>Smoking</b>	0.02	0.86	0.03	0.83

<b>EF</b>	-0.12	0.39	-0.13	0.35
<b>E/e' ratio</b>	-0.34	0.06	-0.35	0.06
<b>Left atrial (mm)</b>	0.04	0.78	0.09	0.50
<b>Diastolic dysfunction</b>	0.07	0.59	0.05	0.72
<b>EOS.count</b>	0.08	0.59	0.10	0.45
<b>IgE</b>	-0.13	0.37	-0.11	0.43

Abbreviation: 6MWT (Six minute walking test), BMI (Body mass index), HS-CRP (High sensitivity C reactive protein), CAT(Chronic obstructive pulmonary disease assessment test), mMRC (modified medical research council), E/e' ratio (the ratio of the trans-mitral early peak velocity over early diastolic mitral annulus velocity), EF (Ejection fraction), LA (left atrial), EOS.count (Eosinophil count)

452

**Table 4-1 Multivariable regression model for distance as assessed by 6MWT**

variable	Beta	*SE	t value	p-value
<b>Age</b>	-3.1	1.2	-2.6	0.01
<b>Synchrogram Index</b>	93.3	42.2	2.2	0.03
<b>mMRC</b>	-37.9	12.9	-2.9	0.005

$r^2 = 0.56$ , adjusted  $r^2 = 0.51$ , Residual stand error = 60.9,  $p < 0.0001$ , Abbreviation: \*SE: stand error of beta.

Distance =  $671.3 + 93.3 \times \text{Synchrogram Index} - 3.1 \times \text{Age} - 37.9 \times \text{mMRC}$

**Table 4-2 Multivariable regression model for DSP as assessed by 6MWT**

variable	Beta	*SE	t value	p
<b>Age</b>	-2.8	1.1	-2.4	0.02
<b>Synchrogram Index</b>	89.1	39.0	2.3	0.03
<b>CAT score</b>	-0.9	1.6	-0.6	0.57
<b>mMRC</b>	-40.7	14.3	-2.8	0.007
<b>Emphysema</b>	-41.1	19.6	-2.1	0.04

$r^2 = 0.63$ , adjusted  $r^2 = 0.58$ , Residual stand error = 56.3,  $p < 0.0001$ , Abbreviation: DSP (Distance saturation product),

SE: Stand error of beta. DSP =  $619.2 + 89.1 \times \text{Synchrogram Index} - 2.8 \times \text{Age} - 40.7 \times \text{mMRC} - 41.1 \times \text{Emphysema}$

453

454 **Legends**

455 Figure 1 Flow chart.

456 Figure 2 (a1) respiratory flow signal (a2) phase of the flow signal extracted by the  
457 SST, (a3) phase of the IHR extracted by the synchrosqueezing transform (SST), (a4)  
458 instantaneous heart rate (IHR), (a5) Electrocardiogram, (a6) synchrogram during 110  
459 (sec) to 125 (sec) (a7) synchrogram and the resulting synchrogram index (0.89) in a  
460 synchronized patient.

461 (b1) respiratory flow signal (b2) phase of the flow signal extracted by the SST, (b3)  
462 phase of the IHR extracted by the SST, (b4) IHR, (b5) Electrocardiogram, (b6)  
463 synchrogram during 110 (sec) to 125 (sec) (b7) synchrogram and its synchrogram  
464 index (0.35) in a desynchronized patient.

465 Figure 3 (a) Distribution of synchrogram index in synchronized group and  
466 desynchronized group. (b) Scatterplot of synchrogram index against distance (m)  
467 from six-minute walking test of all patients (c) Scatterplot of synchrogram index  
468 against distance saturation product (m%) from six-minute walking test of all patient

469

# Figures






Figure 1

Flow chart.



**Figure 2**

(a1) respiratory flow signal (a2) phase of the flow signal extracted by the SST, (a3) phase of the IHR extracted by the synchrosqueezing transform (SST), (a4) instantaneous heart rate (IHR), (a5) Electrocardiogram, (a6) synchrogram during 110 (sec) to 125 (sec) (a7) synchrogram and the resulting synchrogram index (0.89) in a synchronized patient. (b1) respiratory flow signal (b2) phase of the flow signal extracted by the SST, (b3) phase of the IHR extracted by the SST, (b4) IHR, (b5) Electrocardiogram, (b6) synchrogram during 110 (sec) to 125 (sec) (b7) synchrogram and its synchrogram index (0.35) in a desynchronized patient.



**Figure 3**

(a) Distribution of synchrogram index in synchronized group and desynchronized group. (b) Scatterplot of synchrogram index against distance (m) from six-minute walking test of all patients (c) Scatterplot of synchrogram index against distance saturation product (m%) from six-minute walking test of all patient